Xencor, Inc. (NASDAQ:XNCR) Receives $24.88 Consensus Target Price from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $24.8750.

Several analysts have recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a research note on Thursday, November 6th. Cantor Fitzgerald increased their price target on Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. decreased their price objective on Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Royal Bank Of Canada upped their target price on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, Truist Financial began coverage on shares of Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 target price on the stock.

Insider Buying and Selling at Xencor

In other news, CEO Bassil I. Dahiyat sold 114,377 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the completion of the transaction, the chief executive officer directly owned 466,635 shares of the company’s stock, valued at approximately $7,330,835.85. This represents a 19.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP John R. Desjarlais sold 73,367 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $15.72, for a total value of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares in the company, valued at approximately $3,718,943.28. The trade was a 23.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Xencor

Several hedge funds have recently added to or reduced their stakes in the stock. Hantz Financial Services Inc. lifted its position in shares of Xencor by 209.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 2,156 shares during the last quarter. GAMMA Investing LLC raised its stake in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC purchased a new stake in Xencor in the third quarter valued at $44,000. Tower Research Capital LLC TRC boosted its stake in Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 3,018 shares in the last quarter. Finally, Federated Hermes Inc. grew its holdings in shares of Xencor by 114.3% during the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 2,105 shares during the last quarter.

Xencor Stock Performance

Shares of XNCR opened at $11.59 on Friday. The company’s 50-day simple moving average is $14.08 and its 200-day simple moving average is $12.55. Xencor has a 1 year low of $6.92 and a 1 year high of $18.69. The stock has a market capitalization of $827.64 million, a PE ratio of -6.55 and a beta of 0.98.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.